Markets

AstraZeneca investors balk at Bristol Myers deal prospect

RTE August 4, 2026

AstraZeneca investors balk at Bristol Myers deal prospect skip to main content Your browser does not support Javascript.

Please turn Javascript on to get the best experience from rte.ie News Sport Entertainment Business Lifestyle Culture

Gaeilge Player Tv Radio Weather Login News Sport Entertainment Business Lifestyle Culture Player TV Radio Gaeilge

Weather Archives Brainstorm History Discover Discover RTÉ Games RTÉ Archives RTÉ Brainstorm History Gaeilge RTÉ

Learn Food RTÉ Food RTÉ Recipes Watch Watch RTÉ Player TV RTÉ One RTÉ2 RTÉ News RTÉjr Listen Listen Radio

Podcasts RTÉ Radio 1 RTÉ 2FM RTÉ lyric fm RTÉ Raidió na Gaeltachta Services Services Orchestra RTÉ Weather Century

Ireland Kids Kids RTÉ Kids RTÉ Learn Help Help Contact Feedback Accessibility Complaints Terms & Conditions Individual

Rights Guide Privacy Policy Cookie Policy Freedom of Information Helplines Information Information About RTÉ TV Licence

Vacancies Latest Annual Report Advertise with RTÉ 2rn Saorview Newsletters RTÉ Supporting the Arts Policies and

Reports See all results news Business Agribusiness Focus on Inflation Business of Climate Work Brexit Watch and Listen

Your Money Technology Markets Economy Analysis AstraZeneca investors balk at prospect of $400 billion Bristol Myers

pharma deal Updated / Tuesday, 4 Aug 2026 11:03 Investors and analysts said AstraZeneca - the UK's biggest

drugmaker - had little need for a transformative acquisition despite potential cost benefits AstraZeneca investors

punished the pharmaceutical firm yesterday over reports of merger talks with US rival Bristol Myers Squibb that could

make one of the world's biggest drugmakers with a combined value of nearly $400 billion. Shares in AstraZeneca closed

down some 9% yesterday, the biggest drop since 2020, as investors and analysts said Britain's biggest drugmaker had

little need for a transformative acquisition despite potential cost benefits. A deal, if confirmed, would create the

world's fourth-largest drugmaker by market value and the largest by revenue, in potentially one of the biggest M&A

deals ever, combining a top European pharmaceutical firm with a major US rival. An AstraZeneca spokesperson declined to

comment yesterday. Bristol Myers, which is headquartered in New Jersey, did not respond to a request for comment. "The

only advantage for AstraZeneca in this rumoured combination with BMS seems to be to accelerate its US footprint and

sales," said Lucy Coutts, investment director at JM Finn, an AstraZeneca shareholder. "On balance, BMS shareholders

would be the winners of any combination with AZN and so this news will undoubtedly be received coolly by AZN

shareholders." A person familiar with the matter told Reuters that AstraZeneca and Bristol had held talks, confirming an

earlier Financial Times report. On Friday, the two had a combined market capitalisation of nearly $400 billion, with

AstraZeneca valued at $264 billion and Bristol Myers at $133 billion. Analysts and investors questioned the logic of a

deal for AstraZeneca, which has been one of the most successful companies in the sector under CEO Pascal Soriot's 14

years at the helm. We need your consent to load this rte-player contentWe use rte-player to manage extra content that

can set cookies on your device and collect data about your activity. Please review their details and accept them to load

the content.Manage Preferences Markus Manns, portfolio manager at Union Investment, an AstraZeneca shareholder, said a

deal "does not make strategic or financial sense" and that it would disrupt a "well-run company with a full pipeline."

"If the merger rumours prove to be true, this would represent the pharmaceutical industry's equivalent of the FIFA

privatisation moment," added Manns, referring to FIFA's now abandoned plans to sell off a World Cup stake. "(That is to

say a) poorly conceived proposal that would be met with considerable bewilderment by many market participants," he

added. Lukas Leu, portfolio manager at AstraZeneca shareholder ATG Healthcare, said a deal could boost margins through

cost synergies and expand reach in neuroscience and cell therapy, but questioned how a combined firm would position

competing drugs. "I am not a big fan of mega-mergers, it kills innovation and agility, and would be growth-dilutive for

AstraZeneca in the near term," he said. One attraction for AstraZeneca could be further expanding its presence in the

US, already its biggest market. AstraZeneca this year completed a direct listing on the New York Stock Exchange, and a

Bristol Myers deal would effectively mean a British company buying a major US pharmaceutical champion. Bristol Myers

derives the majority of its revenue from the US, where it has one of the largest commercial footprints. A portfolio

manager at a top-20 AstraZeneca shareholder, who commented on condition of anonymity, said that while "there may be an

appeal to increasing US exposure", such a deal "would be a surprise given Astra management has consistently backed the

business to grow organically through R&D delivery". "Consensus is that Astra has a stronger pipeline and less patent

expiry pressure than BMS, so why dilute that and reduce the growth outlook?" Since President Donald Trump returned to

office, AstraZeneca has invested tens of billions of dollars in US manufacturing and cultivated close ties with the

administration as the company pursues an ambitious goal of generating half of its targeted $80 billion in annual revenue

by 2030 from the US market. It generated about $59 billion in revenue last year. Sean Conroy, an analyst at Shore

Capital, said a deal could also help AstraZeneca address the patent cliff it faces after 2030 and strengthen its

oncology business, although he cautioned that investors were "not often fans of mega mergers of this ilk". He added that

overlap between Bristol Myers' Opdivo and AstraZeneca's Imfinzi, which are the same type of cancer immunotherapy drugs,

could attract antitrust scrutiny. More stories on News Business Astrazeneca Business Watch and Listen Bristol Myers

Squibb Pharmaceuticals Source: Reuters News Sport Entertainment Business Lifestyle Culture Player TV Radio Gaeilge